The estimated Net Worth of Christopher Michael Cashman is at least $463 mil dollars as of 18 March 2019. Christopher Cashman owns over 31,662 units of Marinus Pharmaceuticals Inc stock worth over $377,278 and over the last 10 years Christopher sold MRNS stock worth over $85,559.
Christopher has made over 9 trades of the Marinus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Christopher exercised 31,662 units of MRNS stock worth $32,928 on 18 March 2019.
The largest trade Christopher's ever made was exercising 80,830 units of Marinus Pharmaceuticals Inc stock on 8 October 2014 worth over $84,063. On average, Christopher trades about 14,551 units every 108 days since 2014. As of 18 March 2019 Christopher still owns at least 271,423 units of Marinus Pharmaceuticals Inc stock.
You can see the complete history of Christopher Cashman stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is 170 N Radnor Chester Rd #250, Radnor, PA 19087, USA.
Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves..., eAnand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: